Research And Development Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Amifampridine (N07xx05) as Part of a So-Called Open House Model.

Completion of Non-exclusive Drug Discounts According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Cinacalcet (atc Code Who: H05bx01)

Fd2020-23-00458

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Certolizumab Pegol (L04ab05) as Part of an Open House Model.

Fd2020-23-00460

Fd2020-23-00459

Dynamic Procurement System: Remote Monitoring and Management of Waterway Safety Equipment

Northern Rockies Stewardship Bpa

Land Management Integrated Resources (Lmir) National Bpa

Research with Activities Related to Diversity (Reward) (R01 Clinical Trial Optional)